Document 0076
 DOCN  M9610076
 TI    Long-term follow-up of HIV positive asymptomatic patients having
       received cyclosporin A.
 DT    9601
 AU    Levy R; Jais JP; Tourani JM; Even P; Andrieu JM; Departement de Medecine
       Interne, Hopital Laennec, Faculte; Necker, Paris, France.
 SO    Adv Exp Med Biol. 1995;374:229-34. Unique Identifier : AIDSLINE
       MED/96047252
 AB    The data of the 27 asymptomatic HIV-1 seropositive patients with CD4+
       cell count between 300 and 600/microliters treated by Cyclosporin A
       (CSA) (7.5 mg/kg/day) in our institution between October 1985 and 1987
       were reviewed in October 1993. Hemoglobin concentration, platelet count,
       total lymphocytes, CD4+ and CD8+ cell counts and serum core protein p24
       antigenemia, as well as creatininemia measured before CSA onset, at CSA
       cessation and twice a year were recorded as well as clinical signs and
       CSA toxicities. In October 1993 median duration of CSA treatment was 11
       months, median follow-up after CSA cessation was 45 months and median
       total follow-up was 67 months. Toxicities of CSA were those commonly
       encountered in other pathologies. Under CSA no patient progressed toward
       clinical AIDS (1987 definition). The mean CD4+ cell count of the 27
       patients remained unchanged (gain of 1 cell/year) under CSA treatment,
       while it decreased at a rate of 50 cells/year after CSA cessation (p <
       0,005). On the other hand CSA treatment had no significant impact on the
       evolution of total lymphocyte count, CD8+ cell counts, and P24
       antigenemia.
 DE    Adult  Aged  Case-Control Studies  Cyclosporine/ADVERSE
       EFFECTS/*THERAPEUTIC USE  Female  Follow-Up Studies  Human  HIV
       Seropositivity/*DRUG THERAPY  Immunosuppressive Agents/ADVERSE
       EFFECTS/*THERAPEUTIC USE  Male  Middle Age  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).